Two Onc Docs

Today’s episode we will cover 2024 updates for localized renal cell carcinoma (RCC). We will discuss risk factors, the presentation, staging, and treatment options. We are so excited to have Dr. Tom Powles and Dr. Brian Rini from the urologic oncology podcast Uromigos sharing their expertise on today's episode as well!

Dr. Larry Einhorn, a pioneer in testicular cancer treatment, shares his groundbreaking insights in the fight against non-seminomatous testicular cancer. He recounts the inspiring story of the first patient treated with platinum-based chemotherapy, showcasing the power of innovation. The discussion delves into effective management strategies, the importance of fertility preservation for patients, and the implications of the TIGER study comparing chemotherapy doses. Einhorn also offers invaluable advice for oncology trainees navigating their careers.

Dr. Larry Einhorn, a distinguished professor of medicine and a pioneer in the field of germ cell tumors, shares invaluable insights on testicular cancer. He discusses the significant advancements in treatment, particularly the introduction of platinum-based chemotherapy, which has dramatically improved cure rates. The conversation also covers the complexities of staging and managing seminomas, including the importance of tumor markers. Additionally, Dr. Einhorn emphasizes the need for proper education in medical training to better equip future professionals in tackling this disease.

Dive into the world of hematopoietic growth factors! Discover how G-CSF plays a crucial role in combating chemotherapy-induced neutropenic fevers. Learn about the complexities of dose-dense chemotherapy, particularly for breast and bladder cancers. Uncover strategies to manage chemotherapy-induced neutropenia and thrombocytopenia with thrombopoietin receptor agonists. Finally, explore the challenges of chemotherapy-induced anemia and the benefits of erythropoietin-stimulating agents, along with their potential risks.

Today marks our 2 year mark of Two Onc Docs! It’s been a while since we’ve done a re-intro so we figured we would re-introduce ourselves and explain why we picked heme/onc as a speciality, and briefly cover our study plans.

This podcast delves into cancer-related fatigue, discussing its definition, diagnosis, and management options. They explore coping strategies like exercise, therapy, and nutritional consultation. Additionally, they touch on treatment options such as steroids, herbal supplements, and psychostimulants for severe fatigue.

Dive into the world of Primary CNS Lymphoma as hosts unravel its impact on older and immunocompromised patients. Discover the complex symptoms and diagnostic challenges, especially in the elderly. Learn about advanced imaging techniques and the delicate balance of steroid use. The discussion moves into staging methods and cutting-edge treatments involving high-dose methotrexate and rituximab. Explore local therapies for patients unable to undergo systemic treatments and the critical timing needed for effective intervention.

Explore the world of non-melanoma cutaneous malignancies such as squamous cell skin cancer and basal cell carcinoma. Get insight into staging, diagnosis, and treatment options, including the importance of thorough workups for suspicious lesions. Learn about high-risk skin cancers, treatment options for unresectable or metastatic cases, and the importance of complete tumor removal for basal cell carcinomas.

Exploring the diagnosis, risk factors, and demographics of malignant pleural mesothelioma. In-depth discussion on BAP1 gene mutation, cancer risks, screening recommendations, symptoms, and diagnostic process. Detailed explanation of staging pleural mesothelioma based on tumor size and lymph node involvement. Treatment strategies for stage 1-3 epithelioid pleural mesothelioma including induction chemotherapy and surgical procedures. Comprehensive treatment strategies for malignant mesothelioma tailored to different stages and histologies.

Exploring the vital role of Bone Modifying Agents like bisphosphonates and Denosumab in reducing skeletal complications for cancer patients. Discussing the impact of breast, prostate, and lung cancers on bone metastasis. Stressing the importance of creatinine clearance cutoffs, dental clearance, and monitoring for side effects prior to treatment. Highlighting the efficacy of these agents in managing metastatic diseases and rare bone sarcomas.